4D Molecular Therapeutics Inc

+0.50 (+2.21%)
Earnings Announcements

4D Molecular Therapeutics Posts Quarterly Loss Per Share Of $0.82

Published: 11/10/2021 21:50 GMT
4D Molecular Therapeutics Inc (FDMT) - 4d Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights.
Q3 Revenue $1.4 Million.
4d Molecular Therapeutics - Looking Ahead to 2022, Expects to Have 5 Product Candidates in Clinical Development in Three Different Therapeutic Areas.
4d Molecular Therapeutics - Currently Expect Cash, Equivalents, to Be Sufficient to Fund Operations Into Second Half of 2024.
Qtrly Loss per Share $0.82.
Revenue is expected to be $0.35 Million
Adjusted EPS is expected to be -$0.85

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.98

More details on our Analysts Page.